

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of March 2024

	31.03.2024	31.12.2023
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	33 721	33 083
Intangible assets	3 476	3 560
Investments in subsidiaries	69	19
Trade receivables	4 978	4 978
Total non-current assets	42 244	41 640
Current assets		
Inventories	13 816	14 303
Trade and other receivables	67 158	66 490
Current corporate income tax	12	12
Cash and cash equivalents	65	60
Total current assets	81 051	80 865
Total assets	123 295	122 505
LIABILITIES		
Equity		
Share capital	84 500	84 500
Reserves	12 800	12 800
Retained earnings	9 173	7 707
Total	106 473	105 007
Non-current liabilities		
Long-term loans	686	879
Deferred tax liabilities	1 113	1 113
Retirement benefit obligations	177	197
Total non-current liabilities	1 976	2 189
Current liabilities		
Trade and other liabilities	4 089	4 768
Short-term loans	9 789	9 791
Current portion of long-term loans	451	507
Other tax liabilities	517	243
Total current liabilities	14 846	15 309
Total liabilities	16 822	17 498
Total equity and liabilities	123 295	122 505

Date of preparation: 22.04.2024

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of March 2024

	31.03.2024	31.03.2023
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	13 361	13 610
Other income	-	30
Total income	13 361	13 640
Carrying amount of goods sold	(609)	(709)
Changes in inventories of finished products and work in progress	341	(257)
Materials and services	(8 255)	(7 573)
Personnel expenses	(2 270)	(1 567)
Depreciation / amortisation expenses	(622)	(867)
Other expenses	(136)	(468)
Finance income	4	27
Finance costs	(188)	(147)
Total expenses	(11 735)	(11 561)
Profit before taxation	1 626	2 079
Corporate income tax expense	(160)	(140)
Profit/Loss for the period	1 466	1 939
Total comprehensive income for the period	1 466	1 939
Earnings per share / in BGN per 1 share /	0.02	0.02

Date of preparation: 22.04.2024

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of March 2024

	31.03.2024	31.03.2023
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	10 019	8 489
Payments to suppliers of materials, goods and services	(5 001)	(4 348)
Payments to personnel	(2 311)	(1 593)
Foreign currency exchange gains/losses	(8)	(2)
Payments of interest and dividends	(160)	(140)
Other proceeds / payments	(1 281)	(1 512)
Net cash flows	1 258	894
Cash flows from investing activities		
Payments on non-current assets acquired	(926)	(699)
Other post/payments for investment activity	(50)	
Net cash flows	(976)	(699)
Cash flows from financial activities		
Proceeds from loans	155	101
Payments on loans	(157)	(109)
Payment of interest, dividends	(145)	(101)
Payments on finance lease	(130)	(130)
Net cash flows	(277)	(239)
Change in cash and cash equivalents	5	(44)
Cash and cash equivalents at the beginning of the period	60	126
Cash and cash equivalents at the end of the period	65	82

Date of preparation: 22.04.2024

Sofia

Prepared by:.....
 / P. Moneva /

Executive
 Director:.....
 /B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of March 2024

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2023	84 500	4 351	8 147	4 591	101 589
Profit/loss for the period				3 400	3 400
Other comprehensive income		18			18
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		18		3 400	3 400
Issue of shares by the owners			284	(284)	
Dividends accrued			284	(284)	
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.12.2023	84 500	4 369	8 431	7 707	105 007
Balance as of 01.01.2024	84 500	4 369	8 431	7 707	105 007
Profit/loss for the period				1 466	1 466
Other comprehensive income					
Total comprehensive income				1 466	1 466
Issue of shares by the owners					
Total amount of income and expenses recognised during the period					
Balance as of 31.03.2024	84 500	4 369	8 431	9 173	106 473

Date of preparation: 22.04.2024
Sofia

Prepared by:.....
/P. Moneva/

Executive Director:.....
/B. Georgiev/